Table 2.

Baseline biomarker measurements and differences between cases and controls

Median (IQR)				Mean (95% CI)b		Mean difference (95% CI)b
Cases		Controls	pa	Cases	Controls	Case-Control	pb
pNGAL (ng/ml)	177.92 (93.15, 279.46)	118.58 (82.54, 165.69)	0.06	193.02 (140.93, 245.11)	125.56 (73.47, 177.65)	67.46 (−6.21, 141.13)	0.07
pIL-18 (pg/ml)	317.37 (263.41, 443.47)	357.48 (259.19, 442.40)	0.86	377.27 (296.08, 458.46)	345.66 (264.47, 426.85)	31.61 (−83.22, 146.43)	0.57
pL-FABP (ng/ml)	130.14 (95.24, 150.18)	130.74 (91.04, 153.24)	0.44	131.33 (111.69, 150.96)	129.82 (110.18, 149.45)	1.51 (−26.26, 29.28)	0.91
uNGAL (ng/ml)	98.75 (10.10, 347.00)	11.55 (9.38, 185.00)	0.21	553.65 (18.93, 1088.38)	197.31 (−337.41, 732.03)	356.34 (−399.87, 1112.56)	0.34
uIL-18 (pg/ml)	8.66 (7.36, 12.92)	8.95 (5.14, 13.08)	0.84	26.15 (3.88, 48.41)	11.28 (−10.98, 33.55)	14.86 (−16.63, 46.35)	0.34
uL-FABP (ng/ml)	12.49 (5.22, 41.23)	8.05 (2.53, 29.09)	0.26	33.59 (10.58, 56.61)	29.74 (5.85, 53.62)	3.85 (−24.20, 31.90)	0.78
uNGAL/Cr (ng/ml per mg/dl)	2.67 (0.35, 9.73)	0.50 (0.22, 4.15)	0.14	14.57 (3.10, 26.04)	4.83 (−6.64, 16.30)	9.74 (−6.48, 25.96)	0.23
uIL-18/Cr (pg/ml per mg/dl)	0.25 (0.19, 0.36)	0.27 (0.12, 0.36)	0.89	1.24 (−0.11, 2.58)	0.29 (−1.06, 1.63)	0.95 (−0.95, 2.85)	0.31
uL-FABP/Cr (ng/ml per mg/dl)	0.36 (0.14, 1.17)	0.15 (0.08, 0.75)	0.32	1.19 (0.37, 2.00)	0.90 (0.06, 1.73)	0.29 (−0.52, 1.10)	0.46
GFR (ml/min per 1.73 m2)	35.59 (27.06, 43.39)	46.85 (34.38, 58.66)	0.03*	37.77 (30.94, 44.61)	50.14 (43.30, 56.98)	−12.37 (−21.80, −2.93)	0.01*

^asigned rank test,

^blinear mixed effects models

Interquartile range (IQR), confidence interval (CI), plasma (p), urine (u), neutrophil gelatinase-associated lipocalin (NGAL), interleukin 18 (IL-18), liver-type fatty acid binding protein (L-FABP), creatinine (Cr), glomerular filtration rate (GFR).

^*Clinical significance (p < 0.05)